BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17113676)

  • 1. Insulin glulisine imparts effective glycaemic control in patients with Type 2 diabetes.
    Rayman G; Profozic V; Middle M
    Diabetes Res Clin Pract; 2007 May; 76(2):304-12. PubMed ID: 17113676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of preprandial vs. postprandial insulin glulisine on weight and glycaemic control in patients initiating basal-bolus regimen for type 2 diabetes: a multicenter, randomized, parallel, open-label study (NCT00135096).
    Ratner R; Wynne A; Nakhle S; Brusco O; Vlajnic A; Rendell M
    Diabetes Obes Metab; 2011 Dec; 13(12):1142-8. PubMed ID: 21812890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of insulin glulisine as mono- or add-on therapy in patients with type 2 diabetes mellitus.
    Kawamori R; Iwamoto Y; Kadowaki T; Iwasaki M; Kim SW; Woo JT; Baik SH; Yoon KH
    Diabetes Obes Metab; 2009 Sep; 11(9):900-9. PubMed ID: 19614946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs.
    Lankisch MR; Ferlinz KC; Leahy JL; Scherbaum WA;
    Diabetes Obes Metab; 2008 Dec; 10(12):1178-85. PubMed ID: 19040645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes.
    Christiansen JS; Vaz JA; Metelko Z; Bogoev M; Dedov I
    Diabetes Obes Metab; 2003 Nov; 5(6):446-54. PubMed ID: 14617231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study.
    Owens DR; Luzio SD; Sert-Langeron C; Riddle MC
    Diabetes Obes Metab; 2011 Nov; 13(11):1020-7. PubMed ID: 21679291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
    Fulcher GR; Gilbert RE; Yue DK
    Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine.
    Garg SK; Rosenstock J; Ways K
    Endocr Pract; 2005; 11(1):11-7. PubMed ID: 16033730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telecare Provides comparable efficacy to conventional self-monitored blood glucose in patients with type 2 diabetes titrating one injection of insulin glulisine-the ELEONOR study.
    Del Prato S; Nicolucci A; Lovagnini-Scher AC; Turco S; Leotta S; Vespasiani G;
    Diabetes Technol Ther; 2012 Feb; 14(2):175-82. PubMed ID: 22013886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P; Cooper J; Bregnhøj J; Pedersen CB
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes.
    Dailey G; Rosenstock J; Moses RG; Ways K
    Diabetes Care; 2004 Oct; 27(10):2363-8. PubMed ID: 15451901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of insulin glulisine in Japanese patients with type 1 diabetes mellitus.
    Kawamori R; Kadowaki T; Ishii H; Iwasaki M; Iwamoto Y
    Diabetes Obes Metab; 2009 Sep; 11(9):891-9. PubMed ID: 19614947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.
    Blonde L; Merilainen M; Karwe V; Raskin P;
    Diabetes Obes Metab; 2009 Jun; 11(6):623-31. PubMed ID: 19515182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin glulisine.
    Robinson DM; Wellington K
    Drugs; 2006; 66(6):861-9. PubMed ID: 16706558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.
    Bretzel RG; Nuber U; Landgraf W; Owens DR; Bradley C; Linn T
    Lancet; 2008 Mar; 371(9618):1073-84. PubMed ID: 18374840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).
    Garber AJ; Wahlen J; Wahl T; Bressler P; Braceras R; Allen E; Jain R
    Diabetes Obes Metab; 2006 Jan; 8(1):58-66. PubMed ID: 16367883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus.
    Herz M; Sun B; Milicevic Z; Erickson P; Fövènyi J; Grzywa M; Pelikanova T
    Clin Ther; 2002 Jan; 24(1):73-86. PubMed ID: 11833837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
    Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
    Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.